[go: up one dir, main page]

WO2008121261A3 - Prodrugs of triciribin suitable for treatment of tumors and cancer - Google Patents

Prodrugs of triciribin suitable for treatment of tumors and cancer Download PDF

Info

Publication number
WO2008121261A3
WO2008121261A3 PCT/US2008/003853 US2008003853W WO2008121261A3 WO 2008121261 A3 WO2008121261 A3 WO 2008121261A3 US 2008003853 W US2008003853 W US 2008003853W WO 2008121261 A3 WO2008121261 A3 WO 2008121261A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
tumors
cancer
treatment
triciribin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003853
Other languages
French (fr)
Other versions
WO2008121261A2 (en
Inventor
Lawrence Akinsanmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIOQUEST PHARMACEUTICALS Inc
Original Assignee
VIOQUEST PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VIOQUEST PHARMACEUTICALS Inc filed Critical VIOQUEST PHARMACEUTICALS Inc
Publication of WO2008121261A2 publication Critical patent/WO2008121261A2/en
Publication of WO2008121261A3 publication Critical patent/WO2008121261A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This application encompasses prodrugs of triciribine and related compounds and therapeutic regimens of prodrugs of triciribine and related compounds and compositions for the treatment of tumors, cancer, and other disorders associated with abnormal cell proliferation. The application further encompasses oral formulations of prodrugs with increased bioavailabilty, which allows a new route of administration with the attendant clinical benefits of ease of administration.
PCT/US2008/003853 2007-03-28 2008-03-25 Prodrugs of triciribin suitable for treatment of tumors and cancer Ceased WO2008121261A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90730507P 2007-03-28 2007-03-28
US60/907,305 2007-03-28

Publications (2)

Publication Number Publication Date
WO2008121261A2 WO2008121261A2 (en) 2008-10-09
WO2008121261A3 true WO2008121261A3 (en) 2008-12-24

Family

ID=39712321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003853 Ceased WO2008121261A2 (en) 2007-03-28 2008-03-25 Prodrugs of triciribin suitable for treatment of tumors and cancer

Country Status (2)

Country Link
TW (1) TW200902034A (en)
WO (1) WO2008121261A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798185T3 (en) 2012-04-26 2020-12-09 Massachusetts Gen Hospital Agents and methods for the treatment and prevention of seborrheic keratosis
US10508309B2 (en) 2013-05-17 2019-12-17 The General Hospital Corporation Methods for detecting and treating variants of seborrheic keratoses
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2021097401A1 (en) * 2019-11-14 2021-05-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with protein kinase b activation inhibitor to treat cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123524A (en) * 1977-06-08 1978-10-31 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-C]pyridazine-5'-phosphate as a novel compound and its utility against L-1210 mouse leukemia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. J. BODNER ET AL.: "Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 67, no. 5, 1981, US DEPT. OF HEALTH, EDUCATION AND WELFARE, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD; US, pages 1025 - 1030 *
A. R. PORCARI ET AL.: "An Improved Total Synthesis of Triciribine: A Tricyclic Nucleoside with Antineoplastic and Antiviral Properties", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., vol. 23, no. 1, 2004, TAYLOR & FRANCIS, PHILADELPHIA, PA.; US, pages 31 - 39 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12), XP002499547, retrieved from STN Database accession no. 1982:32363 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 February 2004 (2004-02-18), XP002499546, retrieved from STN Database accession no. 2004:131615 *
PORCARI, A. R. ET AL.: "6-N-Acyltriciribine Analogues: Structure-Activity Relationship between Acyl Carbon Chain Length and Activity against HIV-1", JOURNAL OF MEDICINAL CHEMISTRY., vol. 43, no. 12, 2000, AMERICAN CHEMICAL SOCIETY. WASHINGTON; US, pages 2457 - 2463, XP002499362 *

Also Published As

Publication number Publication date
WO2008121261A2 (en) 2008-10-09
TW200902034A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2009064460A3 (en) Gastrointestinal delivery systems
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
BRPI0916356A2 (en)
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008028193A3 (en) Colon-targeted oral formulations of cytidine analogs
WO2005116086A3 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
PH12014501082B1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
UA95975C2 (en) N-methylaminomethyl isoindole compounds, compositions comprising thereof and methods of using the same
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2009146216A3 (en) Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX2010001242A (en) Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same.
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
TN2011000172A1 (en) Therapeutic antiviral peptides
MY145795A (en) Pyrazoline compounds
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
MX2012007217A (en) (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses.
MX2010001243A (en) Anti-inflammatory composition.
WO2008121261A3 (en) Prodrugs of triciribin suitable for treatment of tumors and cancer
WO2008004100A9 (en) Therapeutic compounds
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742227

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC (EPOFORM 1205A DATED 08.03.2010

122 Ep: pct application non-entry in european phase

Ref document number: 08742227

Country of ref document: EP

Kind code of ref document: A2